FGF21 and Hepatic steatosis: In a study using mice with constitutive expression of human AHR specifically in the liver, fibroblast growth factor 21 (FGF21) could be identified as a direct AHR target and a major mediator of both hepatic steatosis and systemic insulin hypersensitivity [61].